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Figure S1. CA-V86M HIV-1 is inhibited by CsA in human lymphocytes and 
macrophages. (A) Activated human CD4
+
 lymphocytes were challenged with WT or 
V86M HIV-1NL-GFP at a multiplicity of infection of ~0.1 in the absence or presence of 2 
µM CsA. WT and V86M viral preparations were adjusted by reverse transcriptase assay. 
The percentage of infected (GFP-positive) cells was determined two days later by flow 
cytometry. Shown are average values from three independent infections with standard 
deviations. (B) THP-1 cells differentiated and polarized into either macrophages (M0), 
pro-inflammatory macrophages (M1) or anti-inflammatory macrophages (M2) were 
challenged with WT or V86M HIV-1NL-GFP exactly like above but at an M.O.I of ~0.02. 
  
Figure S2. Western blotting analysis of CypA knockdown. TE671 cells (top) and Sup-
T1 cells (bottom) expressing the indicated TRIM5αhu mutants and controls were stably 
transduced with retroviral vectors expressing shRNAs targeting either CypA or the non-
relevant control Luciferase. Untransduced cells were eliminated; then, whole cell lysates 
were prepared from a similar numbers of cells and processed for western blotting using 
antibodies against CypA or X-actin as a loading control. 
 
Figure S3. Restriction of WT and CA-V86M HIV-1 by a panel of TRIM5αhu 
mutants. (A) TE671 cells transduced with the indicated TRIM5α cDNAs were 
challenged with multiple doses of WT or CA-V86M HIV-1NL-GFP as described in Figure 
2/29 
1. Cells were analyzed by FACS 2 days later. Control permissive cells transduced with 
the “empty” vector and infected with WT HIV-1NL-GFP are included. (B) TE671 cells 
expressing the indicated TRIM5αhu mutants and controls were challenged with WT or 
V86M HIV-1NL-GFP in the presence of increasing concentrations of CsA. Virus doses 
were adjusted for each virus-cell combination so that approximately 1% of the cells were 
infected in the absence of CsA. The percentage of GFP-positive cells was determined by 
FACS 2 days later and results are shown as –fold increases relative to the no-drug 
controls. 
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